ReviewWorld journal of gastroenterology2019
Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape.
Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2022Pooled it
- Clinical characteristics and treatment patterns of elderly versus non-elderly adults with inflammatory bowel disease in Brazil: a cross-sectional study.BMJ open gastroenterology · 2026Observational
- Review
- Comparative Study on the Management and Outcomes of Postoperative Crohn's Disease in Older Patients: Data From the ENEIDA Registry.United European gastroenterology journal · 2026Article
- Effectiveness of the Crohn's Disease Exclusion Diet for the Treatment of Crohn's Disease in the Older-Adult Population: Real-World Experience.Digestive diseases (Basel, Switzerland) · 2026Article
- The Efficacy and Safety of Thiopurines Do Not Differ Between Geriatric and Non-Geriatric Patients with Inflammatory Bowel Disease.International journal of medical sciences · 2026Article
- Elderly-Onset Inflammatory Bowel Disease Has Distinct Disease Characteristics and Treatment Patterns.United European gastroenterology journal · 2025Article
- Global, regional, and national burden of inflammatory bowel disease in persons aged 60-89 years from 1992 to 2021.BMC gastroenterology · 2025Article
- Frequency of Biological Drug Use in Older Patients with Immune-Mediated Inflammatory Diseases: Results from the Large-Scale Italian VALORE Distributed Database Network.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Advanced Therapies in Elderly Patients With Inflammatory Bowel Disease: A Comparative Retrospective Cohort Study in Taiwan.Therapeutics and clinical risk management · 2025Article
- Bilobalide attenuates lipopolysaccharide‑induced HepG2 cell injury by inhibiting TLR4‑NF‑κB signaling via the PI3K/Akt pathway.Experimental and therapeutic medicine · 2024Article
- Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- Trends and Outcomes of Hip Fracture Hospitalization Among Medicare Beneficiaries with Inflammatory Bowel Disease, 2000-2017.Digestive diseases and sciences · 2021Article
- The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management.Therapeutic advances in gastroenterology · 2021Review
- Inflammatory bowel disease in the elderly: A focus on disease characteristics and treatment patterns.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-quality data remains scarce in terms of optimal management strategies in the elderly inflammatory bowel disease (IBD) population. Indeed, available trials have been mostly retrospective, of small sample size, likely owing to under-representation of such a population in the major randomized controlled trials. However, in the last five years, there has been a steady increase in the number of published trials, helping clarify the estimated benefits and toxicity of the existing IBD armamentarium. In the Everhov trial, prescription strategies were recorded over an average follow-up of 4.2 years. A minority of elderly IBD patients (1%-3%) were treated with biologics within the five years following diagnosis, whilst almost a quarter of these patients were receiving corticosteroid therapy at year five of follow-up, despite its multiple toxicities. The low use of biologic agents in real-life settings likely stems from limited data suggesting lower efficacy and higher toxicity. This minireview will aim to highlight current outcome measurements as it portends the elderly IBD patient, as well as summarize the available therapeutic strategies in view of a growing body of evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.